Science for cure
Providing hope for cancer patients: Our vision for a better future
Imagine a world where cancer patients who lack effective treatment options can be cured. With our innovative cell therapy product, currently in clinical trial, we are bringing this vision closer to reality. Our unique approach trains the patient’s own immune cells to target and eliminate cancer cells, providing a tailor-made treatment for each patient.
NEOGAP – The story
NEOGAP Therapeutics is a privately held clinical stage biopharmaceutical company with the main focus on immuno-oncology.
Discover NEOGAP's innovative pTTL cell therapy and patented technology
Our pTTL cell therapy product, which targets neoantigens, is just one example of our novel technology at NEOGAP. Developed using our proprietary PIOR® and patented EpiTCer® technologies, pTTL generates T cells targeting neoantigens using immune cells from cancer patients as starting material.
The growing colorectal cancer therapeutics market
NEOGAP is dedicated to advancing the field of personalised immunotherapy to combat cancer, starting with our focus on colorectal cancer. Our experienced team of professionals from academia and the pharmaceutical industry is committed to developing innovative solutions that are at the forefront of cancer research. Our pTTL cell therapy product is a testament to this dedication.
We also believe in the power of collaboration and are open to partnering with organisations that share our vision for advancing the field of personalised immunotherapy for cancer treatment.
Latest news from NEOGAP
NEOGAP Therapeutics receives EMA's ATMP classification for its personalised cancer cell therapy
NEOGAP Therapeutics AB, a Swedish clinical-stage biotechnology company, announces that the European Medicines Agency (EMA) has granted Advanced Therapy Medicinal Product (ATMP) classification to its cell therapy, pTTL (personalised Tumour Trained Lymphocytes). This classification confirms that pTTL meets the regulatory criteria for a somatic cell therapy product, providing a clear regulatory pathway for its further development.
Learn more about it here.
NEOGAP Therapeutics partners with NorthX Biologics to advance scalable manufacturing for its novel cancer cell therapy
NEOGAP Therapeutics, a Swedish clinical-stage biotechnology company, has entered a strategic collaboration with NorthX Biologics, a leading CDMO, to advance manufacturing strategies for NEOGAP’s personalised cancer cell therapy. Supported by ongoing funding from the European Innovation Council (EIC) Accelerator, the partnership aims to optimise and scale production for future clinical trials.
Learn more about it here.
NEOGAP featured in an interview with Simsen Diagnostics discussing ongoing study
Ola Nilsson, Head of Neoantigen Production & Development at NEOGAP Therapeutics, provides insights into our personalised T-cell immunotherapy approach in an interview with Simsen Diagnostics. The discussion highlights our ongoing First-In-Human Phase I/II trial for advanced colorectal cancer and our unique treatment methodology, which harnesses patients’ own immune systems — without the need for genetic modification.
Read the complete interview on Simsen Diagnostics’ website.